Results: 1-25 | 26-50 | 51-75 | 76-100 | >>

Table of contents of journal: *Annals of oncology

Results: 1-25/421

Authors: Austoker, J
Citation: J. Austoker, The potential and pitfalls for developing guidelines in oncology, ANN ONCOL, 12(9), 2001, pp. 1189-1190

Authors: Steer, CB Marx, GM Harper, PG
Citation: Cb. Steer et al., Is there quality in clinical benefit?, ANN ONCOL, 12(9), 2001, pp. 1191-1193

Authors: Piccart, MJ Lamb, H Vermorken, JB
Citation: Mj. Piccart et al., Current and future potential roles of the platinum drugs in the treatment of ovarian cancer, ANN ONCOL, 12(9), 2001, pp. 1195-1203

Authors: Vasey, PA
Citation: Pa. Vasey, ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of ovarian cancer, ANN ONCOL, 12(9), 2001, pp. 1205-1207

Authors: Jost, L
Citation: L. Jost, ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of newly diagnosed large cell non-Hodgkin's lymphoma, ANN ONCOL, 12(9), 2001, pp. 1209-1210

Authors: Jost, L
Citation: L. Jost, ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of relapsed large cell non-Hodgkin's lymphoma, ANN ONCOL, 12(9), 2001, pp. 1211-1212

Authors: Wolf, J Jost, L
Citation: J. Wolf et L. Jost, ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of Hodgkin's disease, ANN ONCOL, 12(9), 2001, pp. 1213-1214

Authors: Huddart, RA
Citation: Ra. Huddart, ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of mixed or non-seminomatous germ cell tumours (NSGCT), ANN ONCOL, 12(9), 2001, pp. 1215-1216

Authors: Huddart, RA
Citation: Ra. Huddart, ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of testicular seminoma, ANN ONCOL, 12(9), 2001, pp. 1217-1218

Authors: Greil, R
Citation: R. Greil, ESMO Recommendations for the application of haematopoietic growth factors (hGFs), ANN ONCOL, 12(9), 2001, pp. 1219-1220

Authors: Vansteenkiste, JF Vandebroek, JE Nackaerts, KL Weynants, P Valcke, YJ Verresen, DA Devogelaere, RC Marien, SA Humblet, YP Dams, NL
Citation: Jf. Vansteenkiste et al., Clinical-benefit response in advanced non-small-cell lung cancer: A multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin-vindesine, ANN ONCOL, 12(9), 2001, pp. 1221-1230

Authors: Skarlos, DV Samantas, E Briassoulis, E Panoussaki, E Pavlidis, N Kalofonos, HP Kardamakis, D Tsiakopoulos, E Kosmidis, P Tsavdaridis, D Tzitzikas, J Tsekeris, P Kouvatseas, G Zamboglou, N Fountzilas, G
Citation: Dv. Skarlos et al., Randomized comparison of early versus late hyperfractionated thoracic irradiation concurrently with chemotherapy in limited disease small-cell lung cancer: A randomized phase II study of the Hellenic Cooperative Oncology Group (HeCOG), ANN ONCOL, 12(9), 2001, pp. 1231-1238

Authors: Soini, Y Jarvinen, K Kaarteenaho-Wiik, R Kinnula, V
Citation: Y. Soini et al., The expression of P-glycoprotein and multidrug resistance proteins 1 and 2(MRP1 and MRP2) in human malignant mesothelioma, ANN ONCOL, 12(9), 2001, pp. 1239-1245

Authors: O'Shaughnessy, JA Blum, J Moiseyenko, V Jones, SE Miles, D Bell, D Rosso, R Mauriac, L Osterwalder, B Burger, HU Laws, S
Citation: Ja. O'Shaughnessy et al., Randomized, open-label, phase II trial of oral capecitabine (Xeloda((R))) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer, ANN ONCOL, 12(9), 2001, pp. 1247-1254

Authors: Skovsgaard, T Davidson, NGP Piccart, MJ Richel, DJ Bonneterre, J Cirkel, DT Barton, CM Knight, S
Citation: T. Skovsgaard et al., A phase II study of oral eniluracil/fluorouracil in patients with anthracycline-refractory or anthracycline- and taxane-refractory advanced breast cancer, ANN ONCOL, 12(9), 2001, pp. 1255-1257

Authors: Laufman, LR Spiridonidis, CH Pritchard, J Roach, R Zangmeister, J Larrimer, N Moore, T Segal, M Jones, J Patel, T Gutterman, L Carman, L Colborn, D Kuebler, JP
Citation: Lr. Laufman et al., Monthly docetaxel and weekly gemcitabine in metastatic breast cancer: A phase II trial, ANN ONCOL, 12(9), 2001, pp. 1259-1264

Authors: Zelek, L Barthier, S Riofrio, M Sevin, D Fizazi, K Spielmann, M
Citation: L. Zelek et al., Single-agent estramustine phosphate (EMP) is active in advanced breast cancer after failure with anthracyclines and taxanes, ANN ONCOL, 12(9), 2001, pp. 1265-1268

Authors: Ulrich-Pur, H Kornek, GV Fiebiger, W Gedlicka, C Raderer, M Lenauer, A Depisch, D Lang, F Pidlich, J Scheithauer, W
Citation: H. Ulrich-pur et al., Multicenter phase II trial of dose-fractionated irinotecan in patients with advanced colorectal cancer failing oxaliplatin-based first-line combination chemotherapy, ANN ONCOL, 12(9), 2001, pp. 1269-1272

Authors: Beer, TM Pierce, WC Lowe, BA Henner, WD
Citation: Tm. Beer et al., Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer, ANN ONCOL, 12(9), 2001, pp. 1273-1279

Authors: Kostler, WJ Brodowicz, T Attems, Y Hejna, M Tomek, S Amann, G Fiebiger, WCC Wiltschke, C Krainer, M Zielinski, CC
Citation: Wj. Kostler et al., Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: Results of a phase II trial, ANN ONCOL, 12(9), 2001, pp. 1281-1288

Authors: Punt, CJA Fumoleau, P van de Walle, B Faber, MN Ravic, M Campone, M
Citation: Cja. Punt et al., Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumors. A study by the EORTC-Early Clinical Studies Group (ECSG), ANN ONCOL, 12(9), 2001, pp. 1289-1293

Authors: Quaedvlieg, PFHJ Visser, O Lamers, CBHW Janssen-Heijen, MLG Taal, BG
Citation: Pfhj. Quaedvlieg et al., Epidemiology and survival in patients with carcinoid disease in the Netherlands - An epidemiological study with 2391 patients, ANN ONCOL, 12(9), 2001, pp. 1295-1300

Authors: Di Paolo, A Danesi, R Falcone, A Cionini, L Vannozzi, F Masi, G Allegrini, G Mini, E Bocci, G Conte, PF Del Tacca, M
Citation: A. Di Paolo et al., Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients, ANN ONCOL, 12(9), 2001, pp. 1301-1306

Authors: Rueffer, U Breuer, K Josting, A Lathan, B Sieber, M Manzke, O Grotenhermen, FJ Tesch, H Bredenfeld, H Koch, P Nisters-Backes, H Wolf, J Engert, A Diehl, V
Citation: U. Rueffer et al., Male gonadal dysfunction in patients with Hodgkin's disease prior to treatment, ANN ONCOL, 12(9), 2001, pp. 1307-1311

Authors: Lagrange, JL Ramaioli, A Theodore, C Terrier-Lacombe, MJ Beckendorf, V Biron, P Chevreau, C Chinet-Charrot, P Dumont, J Delobel-Deroide, A D'Anjou, J Chassagne, C Parache, RM Karsenty, JM Mercier, J Droz, JP
Citation: Jl. Lagrange et al., Non-Hodgkin's lymphoma of the testis: A retrospective study of 84 patientstreated in the French anticancer centres, ANN ONCOL, 12(9), 2001, pp. 1313-1319
Risultati: 1-25 | 26-50 | 51-75 | 76-100 | >>